COVID-19 Clinical Trials and Expanded Access

The study explore the relationship between COVID-19 and the induction of autoimmunediseases.

The purpose of the study is to evaluate the presence of early vascular aging 6 months and12 months after COVID-19 infection.

Prospective, single center, randomized, open label, parallel group, 2-arm study assessingthe clinical benefit in term of enhancement of overall response rate of Isatuximab incombination with CellProtect as compared to Isatuximab for the treatment of patients withnewly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) asmaintenance after SCT.

The study investigates how the COVID-19 pandemic has impacted the psychological,financial, physical, and social well-being of adolescent and young adult (AYA) cancerpatients and survivors. AYA cancer survivors have inferior long-term survival compared tothe general population, and the negative impact of the global COVID-19 pandemic may beeven higher in this vulnerable group. The information gained from this study may providean opportunity to determine the self-reported COVID-19 specific psychological distress inAYA cancer survivors, and may lead to the development of a targeted intervention toimprove physical and psychosocial health for AYA cancer patients and survivors.

The intent of this study was to examine the health status of individuals who had beenconfirmed with COVID-19 in the year after their recovery. Parameters studied includedserum levels of SARS coronavirus 2 (SARS-CoV 2) IgG antibody, SARS-CoV-2 nucleic acidtest, hematology indicators (blood routine, liver function, kidney function, myocardialenzymes, coagulation function, etc), lung function test, imaging data and airwaymicrobiota data. In addition, we explored the systematic Immune & Inflammation in some ofthe individuals recovering from COVID-19.

By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients withpneumonia in Wuhan, China. In the following weeks and months the virus spread globally,having a tremendous impact on global health and economy. To date, no vaccine or therapyis available. Severe courses of the infection not only affect the lungs, but also otherorgans like the heart, kidney, or liver. The lack of preexisting immunity might at leastpartially explain the affection of extra pulmonary organs not yet seen in infections dueto other respiratory viruses. In this observational investigation the study group willfollow up on patients that have been hospitalized due to a SARS-CoV-2 infection, andmonitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system.Our that in some patients, organ damage will persist and require long-term medical care.

The aims of the BIBS StudyThe Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby'sbrain develops from before birth, up until 3-4 years of age. Working with children from avariety of backgrounds and communities, the investigators use a combination ofstate-of-the-art diagnostic tools such as MRI scans alongside traditional behaviouralassessments to capture the earliest information on infant brain development.The focus of the BIBS studyMRI scanning is a safe way of producing detailed images using strong magnetic fields andradio waves. It does not use X-ray. Along with learning more about brain development ingeneral, the investigators also try to identify features that may in future help predictwhether a child will or will not develop traits of conditions such as Autism SpectrumDisorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this mayhelp target useful interventions early on, helping children who are most in need.Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have beengiven ethical approval to include testing for this infection in the mothers and childrenparticipating in the study. This may provide an opportunity to better understand howmother and baby respond to infections. The investigators particularly welcome mothers whohave had a positive COVID-19 test during their pregnancy to join the study.

The primary purpose of this study is to gain an understanding of how experiences duringthe COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domainsof health-related quality of life and other areas such as COVID-19 specific psychologicaldistress, and disruptions to health care, finances and social interactions. We will alsoevaluate the extent to which resiliency factors such as social support, perceivedbenefits under times of stress, and ability to manage stress may buffer associationsbetween COVID-19 experiences and HRQoL. To meet these objectives, we have developed a10-minute questionnaire that taps into these areas and is based on prior work addressingconcerns of other pandemics or national crises. Participants will have previouslyconsented to protocol PA15-0336 and have provided prior lifestyle data. This will allowus to connect the COVID-19 survey data with prior existing data.

The CVP-COVID19 registry is both a retrospective and prospective study design in order toidentify predictors of cardiovascular disease progression and mortality for COVID-19. Theregistry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms.The study does not test any new diagnostic or therapeutic approach. Patients are treatedaccording to good clinical practice. Patients characteristics, including medical history(with particular attention to cardiovascular and pneumological risk factors), features ofphysical examination, results laboratory and radiological tests and treatments (pre- andin-hospital) are related with patient outcome. Logistic analysis (univariate,multivariate and propensity) are performed in order to identify factors associated withdisease progression. Primary endpoint: mortality.

This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleicacid analysis platform from, but not limited to, saliva to help enable and supportcontact tracing in the canton of Baselland/ Switzerland. To achieve this, cruderibonucleotide acid (RNA) extraction from saliva is validated in combination withnext-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP)assays as well as point of care test (POCT) for rapid detection of viral antigens onpatients' samples.